During the last session, Protagonist Therapeutics Inc (NASDAQ:PTGX)’s traded shares were 1.36 million, with the beta value of the company hitting 2.30. At the end of the trading day, the stock’s price was $43.09, reflecting an intraday gain of 2.57% or $1.08. The 52-week high for the PTGX share is $60.60, that puts it down -40.64 from that peak though still a striking 41.45% gain since the share price plummeted to a 52-week low of $25.23. The company’s market capitalization is $2.65B, and the average trade volume was 1.24 million shares over the past three months.
Protagonist Therapeutics Inc (PTGX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.18. PTGX has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it.
Protagonist Therapeutics Inc (NASDAQ:PTGX) trade information
Protagonist Therapeutics Inc (PTGX) registered a 2.57% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 2.57% in intraday trading to $43.09, hitting a weekly high. The stock’s 5-day price performance is -5.96%, and it has moved by -0.28% in 30 days. Based on these gigs, the overall price performance for the year is 65.16%.
The consensus price target of analysts on Wall Street is $71.5, which implies an increase of 39.73% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $62 and $76 respectively. As a result, PTGX is trading at a discount of -76.38% off the target high and -43.88% off the low.
While earnings are projected to return -134.64% in 2025.
PTGX Dividends
Protagonist Therapeutics Inc is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 5.76 million shares, is of BLACKROCK INC.’s that is approximately 9.3925% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $199.52 million.
Also, the Mutual Funds coming in first place with the largest holdings of Protagonist Therapeutics Inc (PTGX) shares are iShares Trust-iShares Core S&P Small-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . Data provided on Mar 31, 2025 indicates that iShares Trust-iShares Core S&P Small-Cap ETF owns about 3.69 shares. This amounts to just over 5.95 percent of the company’s overall shares, with a $158.8 million market value. The same data shows that the other fund manager holds slightly less at 1.86, or about 3.00% of the stock, which is worth about $80.05 million.
